Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will speak at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 4:30 PM ET. The conference will highlight the company's focus on women's health, particularly in breast aesthetics and reconstruction markets. A live webcast will be available for interested parties, with an archived version following the event. Establishment Labs is recognized for its Motiva Implants® and other innovative technologies, which are available in over 80 countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced preliminary revenue figures for Q4 and FY 2020. Q4 revenue is expected between $26.5 million and $27.5 million, marking a 10% to 13% increase from $24.2 million in Q4 2019 and up to 20% from Q3 2020. FY 2020 revenue is projected at $84.2 million to $85.2 million, above prior guidance of $80 to $82 million. Cash reserves as of December 31, 2020, are anticipated to be around $84 million, up from $81.4 million in Q3 2020. The CEO highlighted effective contingency planning and market share gains as key contributors to this growth.
Establishment Labs Holdings (NASDAQ: ESTA) announced the receipt of a CE mark for its Motiva Ergonomix2 silicone breast implant platform, which includes the Motiva Ergonomix2 Diamond implant. This approval paves the way for the launch of the Motiva Mia minimally invasive augmentation system in Europe. The Ergonomix2 features advanced materials and patented technology aimed at enhancing patient comfort and minimizing complications. The company anticipates commencing pre-commercial procedures in Europe in the latter half of 2021, significantly shortening the approval timeline by three years.
Establishment Labs (NASDAQ: ESTA) has received Institutional Review Board (IRB) approval for its Motiva Mia system, which features the Ergonomix2 Diamond breast implant. The approval allows the company to initiate a patient series in Costa Rica, with the first procedures already completed on 21 patients. This innovative system aims for minimally invasive breast augmentation with quicker recovery times and less pain. The company is also set to conduct a separate patient series in Thailand, expected to begin in Q1 2021.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focusing on women’s health in breast aesthetics and reconstruction, announced participation in two investment conferences. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will present at the Jefferies Virtual London Healthcare Conference from November 17-19, 2020, and at the Stephens Virtual Investment Conference from November 16-20, 2020. Presentations will be webcast live on their investor relations website, with archived versions available post-event.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q3 2020 revenue of $22.8 million, consistent with the prior year's figure. The company's full-year revenue forecast is set at $80 million to $82 million, supported by a 23% reduction in operating expenses to $17.7 million. This quarter's gross profit reached $15.1 million, representing a margin of 66.6%. The cash balance stood at $81.4 million with a reduced net loss of $2.6 million. New product developments and regulatory advancements bolster future growth potential.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported preliminary third-quarter 2020 revenue between $22 million and $23 million, consistent with $22.9 million from 2019 and significantly up from $10.5 million in Q2 2020. The company's cash balance was approximately $81.0 million as of September 30, 2020. CEO Juan José Chacón-Quirós expressed satisfaction with the quarter's performance, highlighting strong growth and effective cost management. Full third-quarter results will be announced on November 9, 2020.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has amended its distribution agreement with Puregraft LLC to extend their collaboration through the end of 2022. This agreement allows the company to continue offering advanced solutions for fat grafting as part of their MotivaHybrid® procedure, which utilizes the Motiva Implants® for natural breast augmentation. This partnership aligns with Establishment Labs' focus on women's health and expanding its innovative breast aesthetics product line.